{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T11:42:23Z","timestamp":1793187743229,"version":"4.5.0"},"reference-count":65,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2020,8,1]],"date-time":"2020-08-01T00:00:00Z","timestamp":1596240000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2020,8]]},"DOI":"10.1016\/j.ijantimicag.2020.106053","type":"journal-article","created":{"date-parts":[[2020,6,10]],"date-time":"2020-06-10T13:07:42Z","timestamp":1591794462000},"page":"106053","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":97,"title":["Macrolides and viral infections: focus on azithromycin in COVID-19 pathology"],"prefix":"10.1016","volume":"56","author":[{"given":"Arianna","family":"Pani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marinella","family":"Lauriola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Romandini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Scaglione","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ijantimicag.2020.106053_bib0001","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/jac\/dkh519","article-title":"Anti-inflammatory effects of macrolides\u2013an underappreciated benefit in the treatment of community-acquired respiratory tract infections and chronic inflammatory pulmonary conditions","volume":"55","author":"Amsden","year":"2005","journal-title":"J Antimicrob Chemother"},{"issue":"3","key":"10.1016\/j.ijantimicag.2020.106053_bib0002","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1128\/CMR.00078-09","article-title":"Mechanisms of action and clinical application of macrolides as immunomodulatory medications","volume":"23","author":"Kanoh","year":"2010","journal-title":"Clin Microbiol Rev"},{"issue":"5","key":"10.1016\/j.ijantimicag.2020.106053_bib0003","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s00228-011-1161-x","article-title":"Macrolides: from in vitro anti-inflammatory and immunomodulatory properties to clinical practice in respiratory diseases","volume":"68","author":"Zarogoulidis","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"issue":"10223","key":"10.1016\/j.ijantimicag.2020.106053_bib0004","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.ijantimicag.2020.106053_bib0005","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/cmi.2015.74","article-title":"The cytokine storm of severe influenza and development of immunomodulatory therapy","volume":"13","author":"Liu","year":"2016","journal-title":"Cell Mol Immunol"},{"issue":"3","key":"10.1016\/j.ijantimicag.2020.106053_bib0006","doi-asserted-by":"crossref","first-page":"e29879","DOI":"10.1371\/journal.pone.0029879","article-title":"Innate immune response of human alveolar macrophages during influenza A infection","volume":"7","author":"Wang","year":"2012","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.ijantimicag.2020.106053_bib0007","doi-asserted-by":"crossref","first-page":"159","DOI":"10.3855\/jidc.18","article-title":"Macrolides for the treatment of severe respiratory illness caused by novel H1N1 swine influenza viral strains","volume":"3","author":"Bermejo-Martin","year":"2009","journal-title":"J Infect Dev Ctries"},{"key":"10.1016\/j.ijantimicag.2020.106053_bib0008","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.antiviral.2017.05.008","article-title":"Anti-inflammatory effects of adjunctive macrolide treatment in adults hospitalized with influenza: A randomized controlled trial","volume":"144","author":"Lee","year":"2017","journal-title":"Antiviral Res"},{"issue":"1","key":"10.1016\/j.ijantimicag.2020.106053_bib0009","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1186\/s12931-017-0608-8","article-title":"Azithromycin decreases NALP3 mRNA stability in monocytes to limit inflammasome-dependent inflammation","volume":"18","author":"Lendermon","year":"2017","journal-title":"Respir Res"},{"key":"10.1016\/j.ijantimicag.2020.106053_bib0010","doi-asserted-by":"crossref","DOI":"10.1155\/2012\/649570","article-title":"Macrolide therapy in respiratory viral infections","volume":"2012","author":"Min","year":"2012","journal-title":"Mediators Inflamm"},{"issue":"8","key":"10.1016\/j.ijantimicag.2020.106053_bib0011","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1164\/ajrccm.165.8.2103094","article-title":"Erythromycin inhibits rhinovirus infection in cultured human tracheal epithelial cells","volume":"165","author":"Suzuki","year":"2002","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.ijantimicag.2020.106053_bib0012","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1183\/09031936.00029206","article-title":"Clarithromycin in the treatment of RSV bronchiolitis: a double-blind, randomised, placebo-controlled trial","volume":"29","author":"Tahan","year":"2007","journal-title":"Eur Respir J"},{"key":"10.1016\/j.ijantimicag.2020.106053_bib0013","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1743-422X-7-30","article-title":"A new therapeutic strategy for lung tissue injury induced by influenza with CR2 targeting complement inhibitor","volume":"7","author":"Zhang","year":"2010","journal-title":"Virol J"},{"key":"10.1016\/j.ijantimicag.2020.106053_bib0014","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1016\/j.intimp.2016.09.012","article-title":"Azithromycin modulates immune response of human monocyte-derived dendritic cells and CD4(+) T cells","volume":"40","author":"Lin","year":"2016","journal-title":"Int Immunopharmacol"},{"issue":"1","key":"10.1016\/j.ijantimicag.2020.106053_bib0015","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1183\/09031936.06.00008005","article-title":"Effect of clarithromycin on rhinovirus-16 infection in A549 cells","volume":"27","author":"Jang","year":"2006","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.ijantimicag.2020.106053_bib0016","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1124\/jpet.109.162149","article-title":"Clarithromycin inhibits type a seasonal influenza virus infection in human airway epithelial cells","volume":"333","author":"Yamaya","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"issue":"6","key":"10.1016\/j.ijantimicag.2020.106053_bib0017","doi-asserted-by":"crossref","first-page":"L1115","DOI":"10.1152\/ajplung.2001.280.6.L1115","article-title":"Bafilomycin A(1) inhibits rhinovirus infection in human airway epithelium: effects on endosome and ICAM-1","volume":"280","author":"Suzuki","year":"2001","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"3","key":"10.1016\/j.ijantimicag.2020.106053_bib0018","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/S0014-2999(02)02042-3","article-title":"Azithromycin modulates neutrophil function and circulating inflammatory mediators in healthy human subjects","volume":"450","author":"Culic","year":"2002","journal-title":"Eur J Pharmacol"},{"issue":"2","key":"10.1016\/j.ijantimicag.2020.106053_bib0019","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.pharmthera.2014.03.003","article-title":"Azithromycin: mechanisms of action and their relevance for clinical applications","volume":"143","author":"Parnham","year":"2014","journal-title":"Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.ijantimicag.2020.106053_bib0020","first-page":":667-78.","article-title":"Azithromycin suppresses interleukin-12p40 expression in lipopolysaccharide and interferon-gamma stimulated macrophages","volume":"5","author":"Yamauchi","year":"2009","journal-title":"Int J Biol Sci"},{"issue":"1-2","key":"10.1016\/j.ijantimicag.2020.106053_bib0021","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1159\/000358366","article-title":"Macrolides attenuate phorbol ester-induced tumor necrosis factor-alpha and mucin production from human airway epithelial cells","volume":"93","author":"Poachanukoon","year":"2014","journal-title":"Pharmacology"},{"issue":"3","key":"10.1016\/j.ijantimicag.2020.106053_bib0022","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1183\/09031936.00095809","article-title":"Azithromycin induces anti-viral responses in bronchial epithelial cells","volume":"36","author":"Gielen","year":"2010","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.ijantimicag.2020.106053_bib0023","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/j.jcf.2013.08.007","article-title":"Impact of azithromycin treatment on macrophage gene expression in subjects with cystic fibrosis","volume":"13","author":"Cory","year":"2014","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.ijantimicag.2020.106053_bib0024","doi-asserted-by":"crossref","first-page":"40144","DOI":"10.1038\/srep40144","article-title":"Predictive screening of M1 and M2 macrophages reveals the immunomodulatory effectiveness of post spinal cord injury azithromycin treatment","volume":"7","author":"Gensel","year":"2017","journal-title":"Sci Rep"},{"issue":"3","key":"10.1016\/j.ijantimicag.2020.106053_bib0025","doi-asserted-by":"crossref","first-page":"554","DOI":"10.1093\/jac\/dkn007","article-title":"Azithromycin alters macrophage phenotype","volume":"61","author":"Murphy","year":"2008","journal-title":"J Antimicrob Chemother"},{"issue":"50","key":"10.1016\/j.ijantimicag.2020.106053_bib0026","doi-asserted-by":"crossref","first-page":"14408","DOI":"10.1073\/pnas.1618029113","article-title":"Zika virus cell tropism in the developing human brain and inhibition by azithromycin","volume":"113","author":"Retallack","year":"2016","journal-title":"Proc Natl Acad Sci USA"},{"issue":"19","key":"10.1016\/j.ijantimicag.2020.106053_bib0027","doi-asserted-by":"crossref","first-page":"31601","DOI":"10.18632\/oncotarget.16364","article-title":"Azithromycin augments rhinovirus-induced IFNbeta via cytosolic MDA5 in experimental models of asthma exacerbation","volume":"8","author":"Menzel","year":"2017","journal-title":"Oncotarget"},{"issue":"8","key":"10.1016\/j.ijantimicag.2020.106053_bib0028","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1056\/NEJMoa1104623","article-title":"Azithromycin for prevention of exacerbations of COPD","volume":"365","author":"Albert","year":"2011","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.ijantimicag.2020.106053_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.amjmed.2015.07.032","article-title":"Azithromycin for the Prevention of COPD Exacerbations: The Good, Bad, and Ugly","volume":"128","author":"Taylor","year":"2015","journal-title":"Am J Med"},{"issue":"6","key":"10.1016\/j.ijantimicag.2020.106053_bib0030","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/S0002-9343(00)00329-6","article-title":"Effect of clarithromycin on experimental rhinovirus-16 colds: a randomized, double-blind, controlled trial","volume":"108","author":"Abisheganaden","year":"2000","journal-title":"Am J Med"},{"key":"10.1016\/j.ijantimicag.2020.106053_bib0031","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1016\/j.ijid.2019.01.041","article-title":"Macrolides in critically ill patients with Middle East Respiratory Syndrome","volume":"81","author":"Arabi","year":"2019","journal-title":"Int J Infect Dis"},{"issue":"6","key":"10.1016\/j.ijantimicag.2020.106053_bib0032","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1183\/09031936.00004507","article-title":"Antibiotics in RSV bronchiolitis: still no evidence of effect","volume":"29","author":"Kneyber","year":"2007","journal-title":"Eur Respir J"},{"issue":"9","key":"10.1016\/j.ijantimicag.2020.106053_bib0033","doi-asserted-by":"crossref","first-page":"e74316","DOI":"10.1371\/journal.pone.0074316","article-title":"A single dose of azithromycin does not improve clinical outcomes of children hospitalised with bronchiolitis: a randomised, placebo-controlled trial","volume":"8","author":"McCallum","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2020.106053_bib0034","article-title":"In vitro screening of a FDA approved chemical library reveals potential inhibitors of SARS-CoV-2 replication","author":"Franck Touret","year":"2020","journal-title":"bioRxiv"},{"key":"10.1016\/j.ijantimicag.2020.106053_bib0035","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","author":"Gautret","year":"2020","journal-title":"Int J Antimicrob Agents"},{"issue":"4","key":"10.1016\/j.ijantimicag.2020.106053_bib65","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.medmal.2020.03.006","article-title":"No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe COVID-19 infectio","volume":"50","author":"Molina","year":"2020","journal-title":"Med Mal Infect"},{"key":"10.1016\/j.ijantimicag.2020.106053_bib0036","doi-asserted-by":"crossref","DOI":"10.1001\/jama.2020.8630","article-title":"Association of Treatment With Hydroxychloroquine or Azithromycin With In-Hospital Mortality in Patients With COVID-19 in New York State","author":"Rosenberg","year":"2020","journal-title":"JAMA"},{"key":"10.1016\/j.ijantimicag.2020.106053_bib0037","article-title":"Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis","author":"Mandeep","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ijantimicag.2020.106053_bib0038","unstructured":"http:\/\/wayback.archive-it.org\/7993\/20170112032314\/http:\/\/www.fda.gov\/Drugs\/DrugSafety\/ucm304372.htm (accessed april 2020)."},{"key":"10.1016\/j.ijantimicag.2020.106053_bib0039","unstructured":"https:\/\/www.fda.gov\/drugs\/drug-safety-and-availability\/fda-drug-safety-communication-azithromycin-zithromaxor-zmax-and-risk-potentially-fatal-heart (accessed April 2020)."},{"issue":"8","key":"10.1016\/j.ijantimicag.2020.106053_bib0040","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1038\/sj.bjp.0706900","article-title":"No proarrhythmic properties of the antibiotics Moxifloxacin or Azithromycin in anaesthetized dogs with chronic-AV block","volume":"149","author":"Thomsen","year":"2006","journal-title":"Br J Pharmacol"},{"issue":"12","key":"10.1016\/j.ijantimicag.2020.106053_bib0041","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1001\/jama.2013.1937","article-title":"Effect of azithromycin maintenance treatment on infectious exacerbations among patients with non-cystic fibrosis bronchiectasis: the BAT randomized controlled trial","volume":"309","author":"Altenburg","year":"2013","journal-title":"JAMA"},{"issue":"18","key":"10.1016\/j.ijantimicag.2020.106053_bib0042","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1056\/NEJMp1302726","article-title":"Cardiovascular risks with azithromycin and other antibacterial drugs","volume":"368","author":"Mosholder","year":"2013","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ijantimicag.2020.106053_bib0043","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1097\/01.JAA.0000511033.34198.95","article-title":"Is cardiovascular risk a concern when prescribing azithromycin","volume":"30","author":"Sutton","year":"2017","journal-title":"JAAPA"},{"issue":"18","key":"10.1016\/j.ijantimicag.2020.106053_bib0044","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1056\/NEJMoa1300799","article-title":"Use of azithromycin and death from cardiovascular causes","volume":"368","author":"Svanstrom","year":"2013","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.ijantimicag.2020.106053_bib0045","doi-asserted-by":"crossref","first-page":"1881","DOI":"10.1056\/NEJMoa1003833","article-title":"Azithromycin and the risk of cardiovascular death","volume":"366","author":"Ray","year":"2012","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.ijantimicag.2020.106053_bib0046","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1370\/afm.1601","article-title":"Azithromycin and levofloxacin use and increased risk of cardiac arrhythmia and death","volume":"12","author":"Rao","year":"2014","journal-title":"Ann Fam Med"},{"issue":"5","key":"10.1016\/j.ijantimicag.2020.106053_bib0047","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1177\/0897190013516503","article-title":"Azithromycin and the risk of cardiovascular complications","volume":"27","author":"Maisch","year":"2014","journal-title":"J Pharm Pract"},{"key":"10.1016\/j.ijantimicag.2020.106053_bib0048","doi-asserted-by":"crossref","DOI":"10.1155\/2018\/1574806","article-title":"Risk Evaluation of Azithromycin-Induced QT Prolongation in Real-World Practice","author":"Choi","year":"2018","journal-title":"Biomed Res Int"},{"issue":"6","key":"10.1016\/j.ijantimicag.2020.106053_bib0049","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00438-18","article-title":"Systematic Review, Meta-analysis, and Network Meta-analysis of the Cardiovascular Safety of Macrolides","volume":"62","author":"Gorelik","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"issue":"3","key":"10.1016\/j.ijantimicag.2020.106053_bib0050","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1161\/01.CIR.93.3.407","article-title":"Extracellular potassium modulation of drug block of IKr. Implications for torsade de pointes and reverse use-dependence","volume":"93","author":"Yang","year":"1996","journal-title":"Circulation"},{"issue":"10","key":"10.1016\/j.ijantimicag.2020.106053_bib0051","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1002\/pds.1637","article-title":"Pharmacoepidemiology of QT-interval prolonging drug administration in critically ill patients","volume":"17","author":"Freeman","year":"2008","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"10.1016\/j.ijantimicag.2020.106053_bib0052","doi-asserted-by":"crossref","first-page":"929","DOI":"10.4269\/ajtmh.2007.77.929","article-title":"Azithromycin\/chloroquine combination does not increase cardiac instability despite an increase in monophasic action potential duration in the anesthetized guinea pig","volume":"77","author":"Fossa","year":"2007","journal-title":"Am J Trop Med Hyg"},{"key":"10.1016\/j.ijantimicag.2020.106053_bib0053","unstructured":"Pfizer Labs, 2013 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2013\/050693s023,050730s031lbl.pdf (accessed April 2020)."},{"issue":"6","key":"10.1016\/j.ijantimicag.2020.106053_bib0054","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0157045","article-title":"Efficacy and Safety of Azithromycin-Chloroquine versus Sulfadoxine-Pyrimethamine for Intermittent Preventive Treatment of Plasmodium falciparum Malaria Infection in Pregnant Women in Africa: An Open-Label, Randomized Trial","volume":"11","author":"Kimani","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ijantimicag.2020.106053_bib0055","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1186\/1475-2875-13-458","article-title":"Efficacy and safety of a combination of azithromycin and chloroquine for the treatment of uncomplicated Plasmodium falciparum malaria in two multi-country randomised clinical trials in African adults","volume":"13","author":"Sagara","year":"2014","journal-title":"Malar J"},{"key":"10.1016\/j.ijantimicag.2020.106053_bib0056","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacc.2020.04.032","article-title":"Inpatient Use of Ambulatory Telemetry Monitors for COVID-19 Patients Treated with Hydroxychloroquine and\/or Azithromycin","author":"Chang","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"4.23","key":"10.1016\/j.ijantimicag.2020.106053_bib0057","article-title":"Effect of High vs Low Doses of Chloroquine Diphosphate as Adjunctive Therapy for Patients Hospitalized With Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection: A Randomized Clinical Trial","volume":"3","author":"Borba","year":"2020","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.ijantimicag.2020.106053_bib0058","article-title":"Safety signals for QT prolongation or Torsades de Pointes associated with azithromycin with or without chloroquine or hydroxychloroquine","author":"Sarayani","year":"2020","journal-title":"Res Social Adm Pharm"},{"issue":"8","key":"10.1016\/j.ijantimicag.2020.106053_bib0059","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1161\/CIRCULATIONAHA.109.192704","article-title":"Prevention of torsade de pointes in hospital settings: a scientific statement from the American Heart Association and the American College of Cardiology Foundation","volume":"121","author":"Drew","year":"2010","journal-title":"Circulation"},{"issue":"21","key":"10.1016\/j.ijantimicag.2020.106053_bib0060","doi-asserted-by":"crossref","first-page":"2590","DOI":"10.1001\/jama.1993.03510210076031","article-title":"Female gender as a risk factor for torsades de pointes associated with cardiovascular drugs","volume":"270","author":"Makkar","year":"1993","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.ijantimicag.2020.106053_bib0061","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1007\/s11096-016-0414-2","article-title":"Risk factors for QTc-prolongation: systematic review of the evidence","volume":"39","author":"Vandael","year":"2017","journal-title":"Int J Clin Pharm"},{"issue":"20","key":"10.1016\/j.ijantimicag.2020.106053_bib0062","doi-asserted-by":"crossref","first-page":"2623","DOI":"10.1016\/j.jacc.2020.04.016","article-title":"Considerations for Drug Interactions on QTc Interval in Exploratory COVID-19 Treatment","volume":"75","author":"Roden","year":"2020","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.ijantimicag.2020.106053_bib0063","article-title":"Cardiac safety of off-label COVID-19 drug therapy: a review and proposed monitoring protocol","author":"Naksuk","year":"2020","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"key":"10.1016\/j.ijantimicag.2020.106053_bib0064","doi-asserted-by":"crossref","first-page":"363","DOI":"10.3389\/fphar.2018.00363","article-title":"Proton Pump Inhibitors and Serum Magnesium Levels in Patients With Torsades de Pointes","volume":"9","author":"Lazzerini","year":"2018","journal-title":"Front Pharmacol"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920302235?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857920302235?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,13]],"date-time":"2025-10-13T17:35:27Z","timestamp":1760376927000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857920302235"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8]]},"references-count":65,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2020,8]]}},"alternative-id":["S0924857920302235"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106053","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2020,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Macrolides and viral infections: focus on azithromycin in COVID-19 pathology","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2020.106053","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"106053"}}